Atypical primary malignant melanoma originating in the spinal canal: A case report and literature review

Zeng,Ying; Zhang,Yong; Zhang,Jing; Jian,Wei; Li,Rongqing; Fu,Qiaofen

doi:10.3892/ol.2023.14020

Atypical primary malignant melanoma originating in the spinal canal: A case report and literature review

Authors:
- Ying Zeng
- Yong Zhang
- Jing Zhang
- Wei Jian
- Rongqing Li
- Qiaofen Fu
View Affiliations

Affiliations: Department of Radiation Oncology, The First Affiliated Hospital of Kunming Medical University, Kunming, Yunnan 650032, P.R. China
Published online on: August 22, 2023 https://doi.org/10.3892/ol.2023.14020
Article Number: 433
Copyright: © Zeng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Central nervous system (CNS) malignant melanomas are rare tumors of the CNS that are thought to arise from aberrant changes in melanocytes of the neural crest or melanocytic elements of the pia mater during early embryonic development. As a rare type of CNS malignant melanoma, only a few cases of primary malignant melanoma in the spinal canal have been reported thus far. The majority of these studies have reported on the diagnosis, radiographic features and gross total resection of primary spinal canal malignant melanoma; however, the prognosis and ideal treatment of patients with residual tumors remain elusive. The current study presented the rare case of a patient with primary malignant melanoma originating from the thoracic spinal canal, without any history of irradiation exposure and with an incompletely resected tumor. Disease‑free survival of >2.5 years was observed in this patient who was treated with concurrent chemoradiotherapy followed by adjuvant chemotherapy with temozolomide and bevacizumab.

View Figures

View References

1	Chang AE, Karnell LH and Menck HR: The national cancer database report on cutaneous and noncutaneous melanoma: A summary of 84,836 cases from the past decade. The American college of surgeons commission on cancer and the American cancer society. Cancer. 83:1664–1678. 1998. View Article : Google Scholar : PubMed/NCBI
2	Fujimoto M, Matsuzaki I, Nishitsuji K, Yamamoto Y, Murakami D, Yoshikawa T, Fukui A, Mori Y, Nishino M, Takahashi Y, et al: Adipophilin expression in cutaneous malignant melanoma is associated with high proliferation and poor clinical prognosis. Lab Invest. 100:727–737. 2020. View Article : Google Scholar : PubMed/NCBI
3	Mastoraki A, Schizas D, Giannakodimos I, Rebakos A, Margaris I, Katsaros I, Vagios I, Vassiliu P and Pikoulis E: Malignant melanoma of the breast: Controversies in the diagnosis and therapeutic management of a rare nosologic entity. Int J Dermatol. 59:1057–1064. 2020. View Article : Google Scholar : PubMed/NCBI
4	Amalinei C, Grigoraș A, Lozneanu L, Căruntu ID, Giușcă SE and Balan RA: The interplay between tumour microenvironment components in malignant melanoma. Medicina (Kaunas). 58:3652022. View Article : Google Scholar : PubMed/NCBI
5	Puyana C, Denyer S, Burch T, Bhimani AD, Mcguire LS, Patel AS and Mehta AI: Primary malignant melanoma of the brain: A population-based study. World Neurosurg. 130:e1091–e1097. 2019. View Article : Google Scholar : PubMed/NCBI
6	Yang K, Oak ASW, Slominski RM, Brożyna AA and Slominski AT: Current molecular markers of melanoma and treatment targets. Int J Mol Sci. 21:35352020. View Article : Google Scholar : PubMed/NCBI
7	Shi YF, Chen YQ, Chen HF and Hu X: An atypical primary malignant melanoma arising from the cervical nerve root: A case report and review of literture. World J Clin Cases. 10:381–387. 2022. View Article : Google Scholar : PubMed/NCBI
8	Iga T, Iwanami A, Funakoshi T, Mikami S, Tsuji O, Nagoshi N, Okada E, Fujita N, Yagi M, Watanabe K, et al: Multifocal primary melanoma of the cervical spinal cord successfully treated by tumorectomy: A case report. Spinal Cord Ser Cases. 4:242018. View Article : Google Scholar : PubMed/NCBI
9	Fu QF, Liu Y, Fan Y, Hua SN, Qu HY, Dong SW, Li RL, Zhao MY, Zhen Y, Yu XL, et al: Alpha-enolase promotes cell glycolysis, growth, migration, and invasion in non-small cell lung cancer through FAK-mediated PI3K/AKT pathway. J Hematol Oncol. 8:222015. View Article : Google Scholar : PubMed/NCBI
10	Liubinas SV, Maartens N and Drummond KJ: Primary melanocytic neoplasms of the central nervous system. J Clin Neurosci. 17:1227–1232. 2010. View Article : Google Scholar : PubMed/NCBI
11	Pappenheim E and Bhattacharji SK: Primary melanoma of the central nervous system. Clinical-pathological report of a case, with survey and discussion of the literature. Arch Neurol. 7:101–113. 1962. View Article : Google Scholar : PubMed/NCBI
12	Yamasaki T, Kikuchi H, Yamashita J, Asato R and Fujita M: Primary spinal intramedullary malignant melanoma: Case report. Neurosurgery. 25:117–121. 1989. View Article : Google Scholar : PubMed/NCBI
13	Hayward RD: Malignant melanoma and the central nervous system. A guide for classification based on the clinical findings. J Neurol Neurosurg Psychiatry. 39:526–530. 1976. View Article : Google Scholar : PubMed/NCBI
14	Fujimori K, Sakai K, Higashiyama F, Oya F, Maejima T and Miyake T: Primary central nervous system malignant melanoma with leptomeningeal melanomatosis: A case report and review of the literature. Neurosurg Rev. 41:333–339. 2018. View Article : Google Scholar : PubMed/NCBI
15	Rodriguez y Baena R, Gaetani P, Danova M, Bosi F and Zappoli F: Primary solitary intracranial melanoma: Case report and review of the literature. Surg Neurol. 38:26–37. 1992. View Article : Google Scholar : PubMed/NCBI
16	Cohn-Cedermark G, Mansson-Brahme E, Rutqvist LE, Larsson O, Johansson H and Ringborg U: Central nervous system metastases of cutaneous malignant melanoma-a population-based study. Acta Oncol. 37:463–470. 1998. View Article : Google Scholar : PubMed/NCBI
17	de Vries E and Coebergh JWW: Melanoma incidence has risen in Europe. BMJ. 331:6982005. View Article : Google Scholar : PubMed/NCBI
18	Huang HY, Park N, Erlandson RA and Antonescu CR: Immunohistochemical and ultrastructural comparative study of external lamina structure in 31 cases of cellular, classical, and melanotic schwannomas. Appl Immunohistochem Mol Morphol. 12:50–58. 2004. View Article : Google Scholar : PubMed/NCBI
19	Küsters-Vandevelde HVN, van Engen-van Grunsven IACH, Küsters B, van Dijk MR, Groenen PJTA, Wesseling P and Blokx WAM: Improved discrimination of melanotic schwannoma from melanocytic lesions by combined morphological and GNAQ mutational analysis. Acta Neuropathol. 120:755–764. 2010. View Article : Google Scholar : PubMed/NCBI
20	Küsters-Vandevelde HVN, Küsters B, van Engen-van Grunsven ACH, Groenen PJTA, Wesseling P and Blokx WAM: Primary melanocytic tumors of the central nervous system: A review with focus on molecular aspects. Brain Pathol. 25:209–226. 2015. View Article : Google Scholar : PubMed/NCBI
21	Carney JA: Psammomatous melanotic schwannoma. A distinctive, heritable tumor with special associations, including cardiac myxoma and the Cushing syndrome. Am J Surg Pathol. 14:206–222. 1990. View Article : Google Scholar : PubMed/NCBI
22	Rodriguez FJ, Stratakis CA and Evans DG: Genetic predisposition to peripheral nerve neoplasia: Diagnostic criteria and pathogenesis of neurofibromatoses, Carney complex, and related syndromes. Acta Neuropathol. 123:349–367. 2012. View Article : Google Scholar : PubMed/NCBI
23	Rothenbuhler A and Stratakis CA: Clinical and molecular genetics of Carney complex. Best Pract Res Clin Endocrinol Metab. 24:389–399. 2010. View Article : Google Scholar : PubMed/NCBI
24	Balakrishnan R, Porag R, Asif DS, Satter AMR, Taufiq M and Gaddam SSK: Primary intracranial melanoma with early leptomeningeal spread: A case report and treatment options available. Case Rep Oncol Med. 2015:2938022015.PubMed/NCBI
25	Salpietro FM, Alafaci C, Gervasio O, La Rosa G, Baio A, Francolini DC, Batolo D and Tomasello F: Primary cervical melanoma with brain metastases. Case report and review of the literature. J Neurosurg. 89:659–666. 1998. View Article : Google Scholar : PubMed/NCBI
26	Troya-Castilla M, Rocha-Romero S, Chocrón-González Y and Marquez-Rivas FJ: Primary cerebral malignant melanoma in insular region with extracranial metastasis: Case report and review literature. World J Surg Oncol. 14:2352016. View Article : Google Scholar : PubMed/NCBI
27	Wang J, Guo ZZ, Wang YJ, Zhang SG and Xing DG: Microsurgery for the treatment of primary malignant intracranial melanoma: A surgical series and literature review. Eur J Surg Oncol. 40:1062–1071. 2014. View Article : Google Scholar : PubMed/NCBI
28	Ma Y, Gui Q and Lang S: Intracranial malignant melanoma: A report of 7 cases. Oncol Lett. 10:2171–2175. 2015. View Article : Google Scholar : PubMed/NCBI
29	Young GJ, Bi WL, Wu WW, Johanns TM, Dunn GP and Dunn IF: Management of intracranial melanomas in the era of precision medicine. Oncotarget. 8:89326–89347. 2017. View Article : Google Scholar : PubMed/NCBI
30	Swetter SM, Thompson JA, Albertini MR, Barker CA, Baumgartner J, Boland G, Chmielowski B, DiMaio D, Durham A, Fields RC, et al: NCCN guidelines^® insights: Melanoma: Cutaneous, version 2.2021. J Natl Compr Canc Netw. 19:364–376. 2021. View Article : Google Scholar : PubMed/NCBI
31	Han CH and Brastianos PK: Genetic characterization of brain metastases in the era of targeted therapy. Front Oncol. 7:2302017. View Article : Google Scholar : PubMed/NCBI
32	Jour G, Ivan D and Aung PP: Angiogenesis in melanoma: An update with a focus on current targeted therapies. J Clin Pathol. 69:472–483. 2016. View Article : Google Scholar : PubMed/NCBI
33	Ferrara N, Hillan KJ, Gerber HP and Novotny W: Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 3:391–400. 2004. View Article : Google Scholar : PubMed/NCBI
34	Corrie PG, Marshall A, Dunn JA, Middleton MR, Nathan PD, Gore M, Davidson N, Nicholson S, Kelly CG, Marples M, et al: Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M): Preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study. Lancet Oncol. 15:620–630. 2014. View Article : Google Scholar : PubMed/NCBI
35	Corrie PG, Marshall A, Nathan PD, Lorigan P, Gore M, Tahir S, Faust G, Kelly CG, Marples M, Danson SJ, et al: Adjuvant bevacizumab for melanoma patients at high risk of recurrence: Survival analysis of the AVAST-M trial. Ann Oncol. 30:2013–2014. 2019. View Article : Google Scholar : PubMed/NCBI
36	Ascierto PA, Mandalà M, Ferrucci PF, Guidoboni M, Rutkowski P, Ferraresi V, Arance A, Guida M, Maiello E, Gogas H, et al: Sequencing of ipilimumab plus nivolumab and encorafenib plus binimetinib for untreated BRAF-mutated metastatic melanoma (SECOMBIT): A randomized, three-arm, open-label phase II trial. J Clin Oncol. 41:212–221. 2023. View Article : Google Scholar : PubMed/NCBI
37	Bai X and Zhou M: The benefit of bevacizumab therapy in patients with refractory vasogenic edema caused by brain metastasis from lung and colon cancers. Front Oncol. 12:8386702022. View Article : Google Scholar : PubMed/NCBI
38	Banks PD, Lasocki A, Lau PKH, Sandhu S, Mcarthur G and Shackleton M: Bevacizumab as a steroid-sparing agent during immunotherapy for melanoma brain metastases: A case series. Health Sci Rep. 2:e1152019. View Article : Google Scholar : PubMed/NCBI
39	Markovic SN, Suman VJ, Javed A, Reid JM, Wall DJ, Erickson LA, Ernstoff M and Anderson DM: Sequencing ipilimumab immunotherapy before or after chemotherapy (Nab-paclitaxel and bevacizumab) for the treatment of BRAFwt (BRAF wild-type) metastatic malignant melanoma: Results of a study of academic and community cancer research United (ACCRU) RU261206I. Am J Clin Oncol. 43:115–121. 2020. View Article : Google Scholar : PubMed/NCBI
40	Shields CL, Dalvin LA, Chang M, Mazloumi M, Fortin P, McGarrey M, Martin A, Yaghy A, Yang X, Vichitvejpaisal P, et al: Visual outcome at 4 years following plaque radiotherapy and prophylactic intravitreal bevacizumab (every 4 months for 2 years) for uveal melanoma: Comparison with nonrandomized historical control individuals. JAMA Ophthalmol. 138:136–146. 2020. View Article : Google Scholar : PubMed/NCBI
41	Chinese guidelines for diagnosis and treatment of melanoma 2018 (English version). Chin J Cancer Res. 31:578–585. 2019. View Article : Google Scholar : PubMed/NCBI